This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gruson, D.
Right arrow Articles by Bébéar, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gruson, D.
Right arrow Articles by Bébéar, C. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2005, p. 1190-1193, Vol. 49, No. 3
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.3.1190-1193.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

In Vitro Development of Resistance to Six and Four Fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, Respectively

D. Gruson,1 S. Pereyre,1 H. Renaudin,1 A. Charron,1 C. Bébéar,1 and C. M. Bébéar1*

Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, Bordeaux, France1

Received 30 July 2004/ Returned for modification 13 October 2004/ Accepted 9 November 2004

Selection of resistant mutants in sequential subcultures with increasing concentrations of six and four different fluoroquinolones was studied for one reference strain each of Mycoplasma pneumoniae and Mycoplasma hominis, respectively. All fluoroquinolones tested selected for resistance, with alterations affecting the quinolone resistance-determining regions of the four target topoisomerase genes.

* Corresponding author. Mailing address: Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France. Phone: (33) 5 57 57 16 25. Fax: (33) 5 56 93 29 40. E-mail: cecile.bebear{at}u-bordeaux2.fr.

Antimicrobial Agents and Chemotherapy, March 2005, p. 1190-1193, Vol. 49, No. 3
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.3.1190-1193.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Degrange, S., Renaudin, H., Charron, A., Pereyre, S., Bebear, C., Bebear, C. M. (2008). Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae. J Antimicrob Chemother 61: 1390-1392 [Full Text]  
  • Yamazaki, T., Sasaki, T., Takahata, M. (2007). Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 51: 2278-2279 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»